CLINICAL TRIALS PROFILE FOR ZORVOLEX
✉ Email this page to a colleague
All Clinical Trials for ZORVOLEX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03304379 ↗ | Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | Completed | Teva Pharmaceutical Industries, Ltd. | Phase 3 | 2017-10-26 | The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: - To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip - To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip |
| NCT03304379 ↗ | Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip | Completed | Regeneron Pharmaceuticals | Phase 3 | 2017-10-26 | The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: - To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip - To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip |
| NCT03949673 ↗ | Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Terminated | Teva Pharmaceutical Industries, Ltd. | Phase 2 | 2019-04-08 | The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs). |
| NCT03949673 ↗ | Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip | Terminated | Regeneron Pharmaceuticals | Phase 2 | 2019-04-08 | The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZORVOLEX
Condition Name
Clinical Trial Locations for ZORVOLEX
Trials by Country
Clinical Trial Progress for ZORVOLEX
Clinical Trial Phase
Clinical Trial Sponsors for ZORVOLEX
Sponsor Name
